Nanomi Recognized with CMO Award for Excellence in Drug Delivery Innovations

Nanomi Earns CMO Award for Leading Drug Delivery Solutions

Nanomi B.V., a Dutch subsidiary of the global pharmaceutical giant Lupin Limited, has recently made headlines for clinching the prestigious CMO Award for Life Science Leadership in Drug Delivery. This recognition was granted during the Drug, Chemical and Associated Technologies Association (DCAT) Week held in New York, a prominent event that showcases advances in drug delivery and innovation within the pharmaceutical sector.

A Mark of Excellence in Drug Delivery

Nanomi's innovative approach to medication delivery has set new standards within the industry. The award serves not only as recognition of their achievements but also as a motivating factor for their commitment to revolutionizing healthcare. Dr. Shahin Fesharaki, the Global Research Head at Lupin, commented on the significance of this acknowledgement, emphasizing how it reflects the company’s dedication to advancing science and how Nanomi's pioneering methods enhance drug delivery systems. This visionary approach aims to significantly improve patient treatment outcomes, solidifying Nanomi's standing as a leader in the pharmaceutical landscape.

History of the CMO Awards

The CMO Leadership Awards, established in 2011, are bestowed by Outsourced Pharma and Life Science Connect in collaboration with Orientation Marketing. These awards honor top outsourcing partners based on feedback from organizations that subcontract their production needs. Notably, for the first time, this year's award was evaluated by a jury, adding an extra layer of credibility and prestige.

Lupin's Global Presence

Lupin Limited stands as a globally influential pharmaceutical firm headquartered in Mumbai, India. The company’s products reach over 100 markets worldwide, demonstrating its extensive reach and impact. Lupin specializes in a variety of pharmaceutical items, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Renowned for its reliability, Lupin has earned the trust of both medical professionals and consumers, particularly in various therapeutic areas such as respiratory diseases, cardiovascular health, diabetes, infectious diseases, gastrointestinal conditions, central nervous system disorders, and women’s health. The enterprise boasts 15 state-of-the-art manufacturing facilities and 7 research centers globally, employing around 23,000 dedicated personnel.

A Commitment to Health and Innovation

Through its subsidiaries — Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions — the company is relentless in its mission to enhance patient health and outcomes. By continuously exploring innovative solutions and technologies, Lupin aims to stay at the forefront of pharmaceutical advancements.

For more insight into Lupin, interested parties can visit www.lupin.com or connect on LinkedIn at Lupin LinkedIn. To learn more about Nanomi, check out www.nanomi.com or visit their LinkedIn page at Nanomi LinkedIn.

Looking Ahead

As the pharmaceutical industry continues to evolve, the recognition of innovative players like Nanomi affirms the critical role that cutting-edge drug delivery solutions will play in the future of healthcare. The journey towards enhancing patient care and treatment efficacy is ongoing, and accolades such as the CMO Award are pivotal in motivating companies to push the boundaries of what's possible in pharmaceutical science.